Methylphenobarbital

Methylphenobarbital (INN), also known as mephobarbital (USAN, JAN) and mephobarbitone (BAN), marketed under brand names such as Mebaral, Mephyltaletten, Phemiton, and Prominal, is a drug which is a barbiturate derivative and is used primarily as an anticonvulsant, but also as a sedative and anxiolytic. It is the N-methylated analogue of phenobarbital and has similar indications, therapeutic value, and tolerability.

Approval history

1935 – Mebaral was introduced by Winthrop Pharmaceuticals.

2001 – Methylphenobarbital discontinued in the UK.

2003 – Mebaral was acquired by Ovation Pharmaceuticals (a specialty pharmaceutical company that acquired under-promoted branded pharmaceutical products).

2009 – Ovation was acquired by Lundbeck, which now markets Mebaral.

2012 – Lundbeck announced that they were abandoning the product in the US as of January 6, 2012. The stated reason was because "the company thoroughly evaluated all avenues for keeping MEBARAL TABLETS available to patients, but ultimately concluded that no matter what steps they [i.e. Lundbeck] took, patients would be forced to transition to a new therapy."

This page contains text from Wikipedia, the Free Encyclopedia - https://wn.com/Methylphenobarbital

Podcasts:

Email this Page Play all in Full Screen Show More Related Videos

back

Most Related
Most Recent
Most Popular
Top Rated

expand screen to full width
repeat playlist
shuffle
replay video
clear playlist restore
images list

PLAYLIST TIME:

Methylphenobarbital

Approval history

Podcasts:

EXPLORE WN.com